← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Simulations Plus, Inc.
Lancaster, CA
$6,472,242
Total funding
12
Grants
Funding over time
peak $1.2M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
FDA$3,698,661 · 7
NIH$2,773,581 · 5
By mechanism
U01$3,698,661 · 7
R44$2,222,097 · 2
R43$551,484 · 3
Investigators at Simulations Plus, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Software for predicting liver injury from biologics drug candidates using data from a human liver microphysiology system$862,693
R44 · FY2022 · TR
Software for predicting liver injury from biologics drug candidates using data from a human liver microphysiology system$834,404
R44 · FY2023 · TR
Improving Similarity Scoring in Drug Discovery: Solving by Solvating$306,872
R43 · FY2024 · GM
Novel In Silico Models for ADMET Using Rapid Estimates of Quantum Chemical Descri$266,358
R44 · FY2010 · CA
Novel In Silico Models for ADMET Using Rapid Estimates of Quantum Chemical Descri$258,642
R44 · FY2009 · CA
Assessment of Transdermal Drug Product Quality and Performance Attributes via Enhanced Virtual Bioequivalence Simulations$253,440
U01 · FY2018 · FD
Assessment of Transdermal Drug Product Quality and Performance Attributes via Enhanced Virtual Bioequivalence Simulations$250,000
U01 · FY2019 · FD
Dermal Drug Product Quality and Bioequivalence Assessment through Advanced MAM and PBPK Simulation$250,000
U01 · FY2021 · FD
Dermal Drug Product Quality and Bioequivalence Assessment through Advanced MAM and PBPK Simulation$250,000
U01 · FY2022 · FD
Development and validation of a workflow to conduct virtual bioequivalence studies using PBBM-PBPK models$249,640
U01 · FY2023 · FD
From Bench to Bioequivalence: In Vitro Mechanistic Understanding of ASD Drug Products in Simulated Gastrointestinal Conditions$249,485
U01 · FY2025 · FD
From Bench to Bioequivalence: In Vitro Mechanistic Understanding of ASD Drug Products in Simulated Gastrointestinal Conditions$249,485
U01 · FY2024 · FD
Development and validation of a workflow to conduct virtual bioequivalence studies using PBBM-PBPK models$249,392
U01 · FY2024 · FD
Development of PBPK simulation for long-acting injectable microspheres$200,000
U01 · FY2017 · FD
PBPK Modeling and Simulation for Ocular Dosage Forms$200,000
U01 · FY2014 · FD
PBPK Modeling and Simulation for Ocular Dosage Forms$200,000
U01 · FY2015 · FD
PBPK Modeling and Simulation for Ocular Dosage Forms$200,000
U01 · FY2016 · FD
Development of PBPK simulation for long-acting injectable microspheres$200,000
U01 · FY2016 · FD
Development of PBPK simulation for long-acting injectable microspheres$197,219
U01 · FY2015 · FD
Development and Validation of a PBPK/PD Modeling Strategy for Ophthalmic Drug Products to Support Translation from Preclinical Species to Human$180,000
U01 · FY2020 · FD